Breast Cancer Drug Shown to Reduce Recurrence Risk 

Even when the disease is caught early, breast cancer recurrence is relatively commonplace — and for survivors, the prospect can be daunting.

A drug developed by Swiss pharmaceutical maker Novartis reduced this risk by a quarter in a large group of early-stage survivors of the most common type of breast cancer, according to clinical trial results presented Friday at the American Society of Clinical Oncology’s (ASCO) annual meeting, offering patients new hope.

Woman Obsessed With Murder TV Shows And Books, Killed Victim ‘Out Of Curiosity’

The study of ribociclib, which belongs to a newer class of drugs known as molecularly targeted therapies, was described as a “very important and practice-changing clinical trial,” by ASCO expert Rita Nanda, who was not involved in the research.

The majority of the two million new breast cancers diagnosed globally are in the early phases of disease, defined as stages I through III.

Culled from Vanguard